Chemed (NYSE:CHE) CEO Kevin Mcnamara Sells 2,000 Shares of Company Stock

Chemed Corporation (NYSE:CHE) CEO Kevin Mcnamara sold 2,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $537.90, for a total transaction of $1,075,800.00. Following the transaction, the chief executive officer directly owned 82,220 shares in the company, valued at approximately $44,226,138. The trade was a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Chemed Price Performance

CHE opened at $533.43 on Friday. The company has a fifty day simple moving average of $514.34 and a 200 day simple moving average of $464.69. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of 25.52, a PEG ratio of 2.08 and a beta of 0.50. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $562.24. The company has a current ratio of 1.11, a quick ratio of 1.08 and a debt-to-equity ratio of 0.27.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.44 by $0.31. The firm had revenue of $690.94 million for the quarter, compared to the consensus estimate of $685.04 million. Chemed had a net margin of 10.61% and a return on equity of 35.18%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.27 EPS. Equities research analysts expect that Chemed Corporation will post 24.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Bank of America reiterated a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Oppenheimer raised their price objective on Chemed from $590.00 to $625.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Weiss Ratings upgraded Chemed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Royal Bank Of Canada lifted their price objective on Chemed from $548.00 to $585.00 and gave the stock a “sector perform” rating in a report on Thursday, October 29th. Finally, UBS Group upped their target price on Chemed from $650.00 to $675.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $603.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Richardson Financial Services Inc. boosted its stake in Chemed by 5,700.0% during the 3rd quarter. Richardson Financial Services Inc. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the period. Fulcrum Asset Management LLP grew its position in Chemed by 121.9% in the 3rd quarter. Fulcrum Asset Management LLP now owns 71 shares of the company’s stock worth $36,000 after purchasing an additional 39 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Chemed in the second quarter valued at approximately $34,000. Versant Capital Management Inc increased its stake in shares of Chemed by 7,500.0% in the second quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock valued at $35,000 after purchasing an additional 75 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new stake in shares of Chemed in the second quarter valued at approximately $36,000. 95.85% of the stock is owned by institutional investors and hedge funds.

About Chemed

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.